Substituted 3-(phenylmethyl)-1H-indole-5-carboxamides and 1-(phenylmethyl)indole-6-carboxamides as potent, selective, orally active antagonists of the peptidoleukotrienes
摘要:
Substituted indole-5-carboxamides and indole-6-carboxamides have been found to be potent and selective antagonists of the peptidoleukotrienes. Initial derivatives of these series (4-[[5-[(cyclopentylmethyl)carbamoyl]-1-methylindol-3-yl]methyl]-3-methoxy-N-[(2-methylphenyl)sulfonyl] benzamide (5a) and 4-[[6-[(cyclopentylmethyl)carbamoyl]-3-methylindol-1-yl]methyl]-3-methoxy-N-[(2-methylphenyl)sulfonyl]benzamide (6a), respectively), when compared to the corresponding indole amides (e.g. 28 and 29), were found to be approximately 10-fold less potent in vitro and substantially less active when administered orally to guinea pigs. Efforts to improve the potency of the title series by variation of the amide, indole, or sulfonamide substituents led to compounds of comparable in vitro potency to ICI 204,219, but of somewhat lower oral activity. A trend which suggested that more lipophilic transposed amides were needed to increase oral activity was exploited with some success and has led to the discovery of 5q (4-[[5-[(2-ethylbutyl)-carbamoyl]-1-ethylindol-3-yl]methyl]-3-methoxy-N-[(2-methylphenyl)sulfonyl]benzamide), a trans-posed amide with subnanomolar affinity for the leukotriene receptor and an oral ED50 of 5 mg/kg in a model of asthma in guinea pigs. In this model, ICI 204,219 was active at 0.4 mg/kg. The absolute bioavailability of 5q has been found to be 28% in the rat, as compared to 68% for ICI 204,219, with significant levels of 5q observed in the blood of rats up to 24 h postdose.
[EN] SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF<br/>[FR] NUCLÉOSIDES, NUCLÉOTIDES SUBSTITUÉS ET LEURS ANALOGUES
申请人:ALIOS BIOPHARMA INC
公开号:WO2014209979A1
公开(公告)日:2014-12-31
Disclosed herein are nucleosides, nucleotides and analogs thereof, pharmaceutical compositions that include one or more of nucleosides, nucleotides and analogs thereof, and methods of synthesizing the same. Also disclosed herein are methods of ameliorating and/or treating a disease and/or a condition, including an infection from a norovirus, with a nucleoside, a nucleotide and an analog thereof.
COMPOSITIONS AND METHODS FOR TREATING HYPERPROLIFERATIVE DISEASE
申请人:Cameron Dale Russell
公开号:US20080171783A1
公开(公告)日:2008-07-17
The present disclosure provides amide-based, non-nucleoside compounds having an inhibitory activity against endogenous polymerases, such as polymerase alpha and polymerase gamma. This disclosure further provides uses of treating hyperproliferative diseases or disorders, such as benign or malignant neoplasms, and more specifically cancers that are sensitive to inhibition of polymerase alpha and polymerase gamma.
This disclosure relates to, in part, the treatment of an organic acidemia in a subject in need thereof via administration of a therapeutically effective amount of compounds that inhibit BCAT2. The disclosure also relates to, in part, methods for identifying a candidate compound for treatment of organic acidemias.
HYDROPHILIC SILICON-RHODAMINE FLUORESCENT PROBES AND USE THEREOF
申请人:AJOU UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION
公开号:US20200340920A1
公开(公告)日:2020-10-29
The present invention relates to a novel near-infrared fluorescent probe having specificity for mitochondria due to a hydrophobic group attached to a silicon-rhodamine core, and the use thereof for mitochondrial detection and cancer diagnosis. The fluorescent probe of the present invention has improved mitochondrial targeting efficiency compared to conventional probes due to a hydrophobic group attached to a silicon-rhodamine core, can detect mitochondria in living tissue with high sensitivity and specificity in a near-infrared (NIR) region (700 to 1,700 nm), and can acquire three-dimensional high-resolution biological images without harming the human body. Due to these advantages, the fluorescent probe can be used not only for mitochondrial detection in cells in the laboratory, but also as a contrast agent or a drug delivery carrier in cancer diagnosis and surgery.